<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953184</url>
  </required_header>
  <id_info>
    <org_study_id>2016yx238</org_study_id>
    <nct_id>NCT02953184</nct_id>
  </id_info>
  <brief_title>Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy</brief_title>
  <official_title>Marched Pair Study of the Standard Chemotherapy 4doxorubicin Plus Cyclophosphamide(AC) 60 + 4 Docetaxel Protocol Versus 4 PLD C35+4 Docetaxel in Neoadjuvant Chemotherapy of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regimen PLD plus cyclophosphamide 4 cycles followed by paclitaxel or docetaxel 4
      cycles(noted in phase II CAPRICE) will be used as experimental group. The regimen will be
      compared to the standard treatment of doxorubicin plus cyclophosphamide(AC) 4 cycles followed
      by paclitaxel or docetaxel 4 cycles[noted in National Comprehensive Cancer Network (NCCN)
      guideline].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose :Anthracycline based chemotherapy regimen is the milestone on the treatment of breast
      cancer . A sequential protocol, using docetaxel or Paclitaxel after an anthracycline-based
      combination is primary treatment for high-risk breast cancer .Despite its efficient antitumor
      activity profile, the use of conventional anthracycline in clinical practice is limited due
      to it's the risk of cardiac toxicity. The meta analysis show that subclinical cardiotoxicity
      was 17.9% whereas the incidence of clinically overt cardiotoxicity was 6.3%. Overall
      cardiovascular events occurred in 10.6%(Lotrisone , Am J Cardiol. 2013).Many patients have
      healed from breast cancer while they are snatched lives because of heart issue from
      chemotherapy using anthracycline. There are a lot of clinical trials exploring the
      possibilities of chemotherapy regimen without anthracycline ,however the recent result has
      shown anthracycline is indispensible for the patients whose axillary nodes are involved or
      triple negative breast cancer (ASCO 2016 ).So our target is to find a kind of anthracycline
      which is of equal efficiency with conventional anthracycline while less cardiac toxicity.
      Pegylated Liposomal Doxorubicin(PLD) is a novel kind of anthracycline. It distributes into
      cardiac cells lowly and releases Doxorubicin (DOX) slower to avoid peak plasma concentration,
      so it is of significant less cardiotoxicity compared to free DOX. It also achieve
      non-inferior efficacy at 50mg/m2 to conventional anthracycline in Metastatic Breast Cancer
      (MBC).( M. E. R. O'Brien, ,Annals of Oncology,2004;).

      PLD 35mg/m2 in combination with paclitaxel showed an overall response rate of 71% ,tolerating
      toxicity of the skin(3% hand-foot syndrome)and rare cardiac event( H. Gogas1, Annals of
      Oncology, 2002;Gil-Gil , Breast Cancer Res Treat. 2015)However, There are a crucial question
      is to know if 35mg/m2 PLD has equivalent efficacy with less cardiac toxicity compared with 60
      mg/m2 DOX in adjuvant chemotherapy for all patients.

      The regimen PLD plus cyclophosphamide 4 cycles followed by paclitaxel or docetaxel 4
      cycles(noted in phase II CAPRICE)will be used as experimental group. The regimen will be
      compared to the standard treatment of doxorubicin plus cyclophosphamide (AC)4 cycles followed
      by paclitaxel or docetaxel 4 cycles(noted in NCCN guideline).

      Condition Intervention Phase

      Individualized Chemotherapy Drug: Pegylated Liposomal Doxorubicin(PLD) Drug: Doxorubicin(DOX)

      Drug: Cyclophosphamide Drug: docetaxel or Paclitaxel Phase 2

      Study Type: Interventional Study Design: Allocation: assignment based on patients desire
      Endpoint Classification: Safety/Efficacy Study Intervention Model: Marched pair Parallel
      Assignment Masking: Open Label Primary Purpose: Treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of pathological complete response（PCR)</measure>
    <time_frame>at th 26th weeks of treatment since recruitment (after 8 cycles of neoadjuvant chemotherapy when the patient will undergo surgery)</time_frame>
    <description>Pathological evaluation after sugary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance according to Common Terminology Criteria Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>at 3rd ,6th,9th,12th, 15 ,18,21,24th weeks since recruitment (after each cycle of chemotherapy) ; half year ,1 year , one and half year ,two years since recruitment</time_frame>
    <description>Cardiogram Cardiac sonography, examination of Cardiac Marker if necessary and Questionaire Survey about Side Effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>at 3rd ,6th,9th,12th, 15 ,18,21,24th weeks since recruitment （after each cycle of chemotherapy）</time_frame>
    <description>ultrasound of breast and Pathological reports</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Antineoplastic Combined Chemotherapy Protocols</condition>
  <arm_group>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>35mg/m2 iv drop during the first 4 cycles every three week</description>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>liposome doxorubicin injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600mg/m2 IV drop during the first 4 cycles every three week</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>100mg/m2 IV drop during the last 4 cycles every three week</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane (DZR)</intervention_name>
    <description>DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <other_name>DZR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin B</intervention_name>
    <description>Vitamin B will be administrated for protecting HFS in PLD group</description>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>Compound Vitamin B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <other_name>Pirarubicin Hydrochloride for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast Conserved Surgery</intervention_name>
    <description>Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>segmental mastectomy and ALND</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified Radical Mastectomy</intervention_name>
    <description>Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>Mastectomy and ALND</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy（SLNB）</intervention_name>
    <description>Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy</description>
    <arm_group_label>conventional Doxorubicin plus C-T</arm_group_label>
    <arm_group_label>PLD plus C -T</arm_group_label>
    <other_name>Sentinel Lymph Node(SLN)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histological proof of invasive cancer, whose clinical tumor diameter is &gt;
             2 cm, or &lt; 2 cm, but Axillary lymphnodes are involved .There is no metastatic Imaging
             findings.

          -  Stage II,III tumor, non-metastatic, grade II - III

          -  Performance Status = 0-1 World Health Organization (WHO).

          -  Patient non pretreated for breast cancer.

          -  Patient without cardiac pathology and without anthracyclines contra-indication
             (assessed by normal ejection fraction).

          -  Normal haematological, renal and hepatic functions : platelets &gt; 100. 109 /l, Hb &gt; 10
             g/dl, normal bilirubin serum , Aspartate transaminase(ASAT) and Alanine
             Aminotransferase(ALAT) &lt; 2,5 Upper Limit of Normal (ULN), alkaline phosphatases &lt; 2,5
             ULN, creatinin &lt; 140 µmol/l or creatinin clearance &gt; 60 ml/min

          -  Written informed consent dated and signed by the patient

        Exclusion Criteria:

          -  All other breast cancers than those described in inclusion criteria, in particular
             inflammatory and/or neglected (T4b or T4d) forms.

          -  Patient presenting with intraduct cancer in situ.(DCIS)

          -  Grade I well differentiated tumor.

          -  Non measurable lesion, in the two diameters, whatever radiological methods used.

          -  Patient already operated for breast cancer or having had primary axillar node
             dissection.

          -  Patient presenting with cancer in other system.

          -  Any psychological, familial, sociological or geographical condition that may
             potentially hamper compliance with the study protocol and follow up schedule, assessed
             with the patient prior to registration in the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiping Shi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Di Wu, Doctor</last_name>
    <phone>0086-13504331975</phone>
    <email>w2000mail@sohu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongyao Jia, Master</last_name>
    <phone>0086-1580430156</phone>
    <email>52272435@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Shi, Doctor</last_name>
      <phone>0086-13364308696</phone>
      <email>13364308696@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhimin Fan, Doctor</last_name>
      <phone>0086-13756661286</phone>
      <email>fanzhimn@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Di Wu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongyao Jia, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Guan, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhimin Fan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haibo Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang Nie, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012 Feb 4;379(9814):432-44. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5.</citation>
    <PMID>22152853</PMID>
  </reference>
  <reference>
    <citation>Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013 Dec 15;112(12):1980-4. doi: 10.1016/j.amjcard.2013.08.026. Epub 2013 Sep 25. Review.</citation>
    <PMID>24075281</PMID>
  </reference>
  <reference>
    <citation>Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9.</citation>
    <PMID>19204201</PMID>
  </reference>
  <reference>
    <citation>Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoulos C. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2002 Nov;13(11):1737-42.</citation>
    <PMID>12419745</PMID>
  </reference>
  <reference>
    <citation>Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.</citation>
    <PMID>25981896</PMID>
  </reference>
  <reference>
    <citation>O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9.</citation>
    <PMID>14998846</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jilin University</investigator_affiliation>
    <investigator_full_name>Aiping shi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>Pegylated liposomal doxorubicin</keyword>
  <keyword>breast cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

